鲍曼不动杆菌感染的诊断与治疗  

Diagnosis and therapy of Acinetobacter baumanii infection

作　　者：宁永忠 杨林[2] 李祥[1] 傅琪瑶 王俊文[1] 

机构地区：[1]清华大学附属北京市垂杨柳医院检验科,100022 [2]河北医科大学检验系,石家庄050017

出　　处：《传染病信息》2017年第5期277-281,共5页Infectious Disease Information

基　　金：北京市科委计划课题(Z161100000516172)

摘　　要：鲍曼不动杆菌是人体正常菌群成员,近年来,该菌所致的特殊人群感染日益增加。该菌感染的诊断要符合感染性疾病诊断的一般原则,但在具体不同部位的感染,其诊断也有特殊要求;在耐药方面,要考虑异质性耐药;在治疗方面,该菌的泛耐药株对治疗构成了挑战,在预防用药、经验治疗、抢先治疗、靶向治疗等方面有一系列进展和共识。本文对上述进展作一综述。此外,本文还介绍了国内治疗最常见的两类药物舒巴坦制剂和替加环素的应用进展。Acinetobacter baumanii is the member of human normal flora. It can cause the infection of special patient population. Acinetobacter baumanii infection＇s diagnosis should be consistent with general principle of infection diseases and has special characteristics in different situations such as bloodstream infection and meningitis. Drug resistance may consider the heteroresistance. Its extensively drug resistant isolate has been the challenge of clinical therapy. There are series of development and consensus in the field of preventive medication, empric therapy, preemptive therapy and target therapy. We also review the development of the drugs including sulbactam and tigecycline, which are the first line drugs in China.

关 键 词：鲍曼不动杆菌 感染 耐药性 抗菌药物 

分 类 号：R378.99[医药卫生—病原生物学]